
Opinion|Videos|April 15, 2025
Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results
Panelists discuss how poorly managed generalized pustular psoriasis (GPP) flares can lead to recurrent hospitalizations and significant morbidity, while reviewing Effisayil 2 trial results that demonstrated the effectiveness of maintenance therapy in preventing flares and sustaining long-term disease control through targeted inhibition of the IL-36 pathway.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
How Galderma is Modernizing Aesthetic Trends and Patient Outcomes Around the World
2
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
3
Dermatology Times January 2026 Print Recap
4
Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo
5








